|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 601 PENNSYLVANIA AVENUE, NW, #740 |
Address2 | |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 31348-12
|
||||||||
|
6. House ID# 340040000
|
TYPE OF REPORT | 8. Year | 2008 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Brenda Palmer, CFO |
Date | 10/20/2008 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues related to Medicare/Medicaid drug coverage including pharmacy payments, reimbursements, competition and plan administration; electronic prescribing
S 3 / HR 4 - Medicare Prescription Drug Price Negotiation Act of 2007
HR 3700 - Fair Medicaid Drug Payment Act of 2007
S 273 - Prescription Drug and Health Improvement Act of 2007
S 3118 - Preserving Access to Medicare Act of 2008
HR 4296 and S 2408 - Medicare Electronic Medication and Safety Protection (E-MEDS) Act of 2007
HR 6331 - Medicare Improvement for Patients and Providers Act of 2008
S 3101 - Medicare Improvements for Patients and Providers Act of 2008
S 1951 - Fair Medicaid Drug Payment Act of 2007
HR 3140 - Saving Our Community Pharmacies Act of 2007
S 1507 - Access to Medicare Data Act of 2007
17. House(s) of Congress and Federal agencies Check if None
White House Office, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Drug Enforcement Administration (DEA), Medicare Payment Advisory Commission (MedPAC), Congressional Budget Office (CBO), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Merritt |
|
|
|
Jonathan |
Heafitz |
|
|
|
Ellen |
Jenkins |
|
|
|
Tim |
Brogan |
|
|
|
Dana |
Sherwood |
|
|
|
Greg |
Johnson |
|
|
|
Barbara |
Levy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Issues related to drug coverage including pharmacy payments, reimbursement, competition and plan administration;
Health Information Technology with respect to data privacy and electronic prescribing of prescription drugs;
Promotion of competition in the prescription drug marketplace including the drug approval process;
Additional Issues - see addendum
Issues related to drug coverage including pharmacy payments, reimbursement, competition and plan administration
HR 1474 - Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims Act of 2007;
HR 3140 - Saving Our Community Pharmacies Act of 2007
HR 3193 - Access to Community Pharmacy Preservation Act of 2007
S 1954 - Pharmacy Access Improvement (PhAIm) Act of 2007
S 2161 - Community Pharmacy Fairness Act of 2007
Health information technology with respect to data privacy and electronic prescribing of prescription drugs
HR 4296 and S 2408 - Medicare Electronic Medication and Safety Protection (E-MEDS) Act of 2007
HR 3800 - Promoting Health Information Technology Act
HR 6357 - Protecting Records, Optimizing Treatment, and Easing Communication through Healthcare Technology Act of 2008 or the PRO(TECH) Act of 2008
HR 6898 - Health e-Information Technology Act
S 1408 - Health Information Technology Act of 2007
S 1693 - Wired for Health Care Quality Act
S. 1814 - Health Information Privacy and Security Act
Promotion of competition in the prescription drug marketplace including the drug approval process
HR 1432 and S. 316 - Preserve Access to Affordable Generics Act
HR 1956 - Patient Protection and Innovative Biologic Medicines Act of 2007
HR 5629 - Pathway for Biosimilars Act
S 28 - Generics First Act of 2007
S 1695 - Biologics Price Competition and Innovation Act of 2007
HR 1038 / S 623 - Access to Life-Saving Medicine Act
S 316 Preserve Access to Affordable Generics Act
HR 1505 / S 1695 Affordable Biologics for Consumers Act
HR 5629 - Pathway for Biosimilars Act
Additional Issues
HR 5683 - Government Accountability Office Act of 2008
S 1507 - Access to Medicare Data Act of 2007
S 273 - Prescription Drug and Health Improvement Act of 2007
HR 3610 - Food and Drug Import Safety Act of 2007
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office, Office of Management & Budget (OMB), Congressional Budget Office (CBO), Medicare Payment Advisory Commission (MedPAC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Merritt |
|
|
|
Jonathan |
Heafitz |
|
|
|
Ellen |
Jenkins |
|
|
|
Tim |
Brogan |
|
|
|
Dana |
Sherwood |
|
|
|
Greg |
Johnson |
|
|
|
Barbara |
Levy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
See Addendum
HR 971 and S 885 / S 2161- Community Pharmacy Fairness Act of 2007
HR 6353 and S. 980 - Ryan Haight Online Pharmacy Consumer Protection Act of 2007
HR 1474 - Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims Act of 2007
HR 3140 - Saving Our Community Pharmacies Act of 2007
HR 3090 - Patient and Pharmacy Protection Act of 2007
HR 3193 Access to Community Pharmacy Preservation Act of 2007
S 596 - Safe Internet Pharmacy Act of 2007
S 1954 - Pharmacy Access Improvement (PhAIm) Act of 2007
S 2161 - Community Pharmacy Fairness Act of 2007
S 877 - Controlling the Abuse of Prescription Act of 2007
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), White House Office, Health & Human Services - Dept of (HHS), Congressional Budget Office (CBO), Office of Management & Budget (OMB), Medicare Payment Advisory Commission (MedPAC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Merritt |
|
|
|
Jonathan |
Heafitz |
|
|
|
Ellen |
Jenkins |
|
|
|
Tim |
Brogan |
|
|
|
Dana |
Sherwood |
|
|
|
Greg |
Johnson |
|
|
|
Barbara |
Levy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LBR
16. Specific lobbying issues
HR 971 and S885 / S2161 - Community Pharmacy Fairness Act of 2007
Issues relating to the Department of Labor's proposed rule with regard to compensation disclosure for various service providers.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Labor - Dept of (DOL), Health & Human Services - Dept of (HHS), White House Office, Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Merritt |
|
|
|
Jonathan |
Heafitz |
|
|
|
Ellen |
Jenkins |
|
|
|
Tim |
Brogan |
|
|
|
Dana |
Sherwood |
|
|
|
Greg |
Johnson |
|
|
|
Barbara |
Levy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |